Anavex og CNS
-
Peer Review S1R - Anavex
Ny opfølgende Peer Review fra samme forskergruppe, der udgav en Peer Review specifik for Anavex 2-73 i marts 2019.
Den nye Peer Review understreger igen, at en S1R som Anavex 2-73 har evnen til at understøtte bl.a. Autophagy
(udrensning/oprydning i cellekernen, således at disse ved deling ikke misfolder )Autophagy menes at være essentiel i hele mekanismen i ældningsprocessen og den generelle sundhedstilstand på celleniveau.
Hovedårsagen til udviklingen af mange CNS sygdomme, er sandsynligvis, at cellerne efterhånden laver dårligere kopier/celledeling, fordi urenheder/defekte dele ikke bliver smidt ud af cellekernen.
I princippet ville en vedvarende fejlfri celledeling således være med til at forsinke ældningsprocessen og forebygge forskellige CNS sygdomme.Igen - dette kan sandsynligvis forklare, hvorfor vi ser Anavex 2-73 have en virkning i så bredt et spektre på CNS området.
Marts 2019:
https://www.mdpi.com/2073-4409/8/3/211TDT123 - ved ikke hvad der får Anavex til at stige og om shorterne bare igen presser kursen ned igen.
Men ingen kan tage den tiltagende styrkede videnskabelige fundament fra Anavex.
En pr. fra Anavex ville dog ikke være dårligt lige nu for at give kursen momentum. -
Short er faldende https://volumebot.com/?s=avxl lad os håbe det fortsætter...
-
Anavex - nyt patent til 2037!
MoneyShow top Picks for 2020.
Profitable Advice from Investing and Trading Experts
Daily articles and videos featuring specific investment recommendations, stock picks and ETF recommendations for investors plus profitable trading strategies and trade ideas from top investing and trading experts.
Profitable Advice from Investing and Trading Experts (www.moneyshow.com)
-
Typisk Anavex så falder den på gode nyheder!
Selv shorts må snart kunne se det absurde i det.
Positiv omtale og endnu et nyt patent helt til 2037, hvor også Multi Skelrose igen er nævnt/omfattet - selvfølgelig skal kursen da ned!
Anavex er nok den eneste aktie, der både falder ved dårlige og gode nyheder.
Mon ikke den kommer op når shorterne har forsøgt deres. -
Så der delt aktier ud https://newsfilter.io/articles/4-form-7563a6bc776b3dc442c7310e0fab5ce7 Lad os håbe at de kære analytiker for en gang skyld har ret
-
Kun warrants, som afhænger af resultaterne i rett. De er til kurs 2,96 det er vist okay
-
Ja MM - right to buy i kurs 2,96 $
550.000 og 50 -70.000 til andre i ledelsen.
Der fremgår ikke spcifikt, hvilken milepæl for RETT det vedrører.
Men man må da forvente en positiv udvikling. så kursen kommer noget over 2,96 - ellers er disse warrants ikke meget værd.
En 100 % indrulning alene i RETT synes dog umiddelbar ikke at være en tilstrækkelig milepæl.Der udløses også warrents ved min. 50 % indrulning i både AD og PK.
Dette må iflg. sidste cc være meget tæt på.Explanation of Responses:
(1) The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome.
https://ih.advfn.com/stock-market/USOTC/anavex-life-sciences-AVXL/stock-news/81492022/statement-of-changes-in-beneficial-ownership-4Vedr. det sidste patent, dukkede Multi Skelrose op igen.
Der har været en del diskution om netop MS, idet Biogen testede 2-73 for ca. 3 år siden.
De skulle sådan set bare eftervise de positive resultater WS ( US universitet ) havde udført tidligere.
Her hørte vi intet om, hvad resultatet endte ud i - men der foregik helt klart et eller andet efter min mening og Anavex var meget kryptisk i deres svar på spørgsmål på området efterfølgende.
I starten havde Anavex også MS i deres pipeline, men har været taget ud igen efter aftalen med Biogen.Ren spekulation fra min side:
Kunne det tænkes, at Anavex/Biogen blev opmærksom på, at deres patentbeskyttelse ikke var fuld dækkende - før nu med dette sidste patent?
Anavex har i flere omgange udtalt, at de undersøger muligheden for out licensing.
Dette ville ingen af parterne i sådan en aftale kunne leve med, hvis patent beskyttelsen ikke var på plads!Men igen - Anavex står stærkere og stærkere som tiden går - og tror vi kan vente lidt af hvert de kommende måneder.
-
http://shortsqueeze.com/shortinterest/stock/AVXL.htm
Jeg håber så meget at den rigtige nyhed lander, og vi så ser en squeeze der sparker røv.....
-
Hej TDT - Anavex shorts
Kan du se hvilken SSQ ranking Anavex har fået af denne side?
En tanke vedr. indrulningsprocenterne:
Mener ikke at det er lovpligtig, at skulle oplyse disse tal.
Anavex har dog lovet at oplyse dette løbene.
Kunne det tænkes, at de bare samler oplysningerne i en Pr.: 100 % i PK, 100 i RETT og så 50 % i AD?
Ud fra sidste cc i december, så det ud til, at disse milepæle ligger megt tæt tidsmæssig.Kl. 13.00 er efterhånden blevet et meget spændende klokkeslet i hverdagene. Anavex har hidtil med at bruge dette tidspunkt til nye pr.
Mener det sidste modtagende patent gør, at Anavex nu kan være mere åbne og frie til agerer på flere fronter.
-
Anavex i Rettsymdromenews!
-
Anavex også i Multiple Sclerosis News Today!
Understreger, at 2-73 stadig i høj grad har pontentiale i MS.
Biogen omsætter for adskillige milliarder hvert år på området, men deres patenter løber ud om relative få år.Anavex er langt mere end en mulig behandling i en enkelt indikation!
Mulighederne for Anavex 2-73 er uanede, fordi det understøtter, beskytter og reetablere grundmekanismerne på et bredt område, som bl.a. nerveceller fungerer på.
Vi mangler bare den sidste vigtige bevis af, at de hidtil sete resultater kan eftervises i et større antal patienter.
MS Included in New US Patent Issued for Anavex 2-73
Anavex received a U.S. patent covering the use of Anavex 2-73 (blarcamesine) for the treatment of conditions including multiple sclerosis and Rett syndrome.
Multiple Sclerosis News Today (multiplesclerosisnewstoday.com)
Anavex 2-73 is an orally available, small-molecule activator of a protein called the sigma-1 receptor (S1R), which is essential to ensure correct protein folding within nerve cells and to promote neuroplasticity - the brain's ability to adapt or rewire following damage to preserve function.
The activation of S1R mediated by Anavex 2-73 is also thought to decrease mitochondria dysfunction, oxidative stress, and inflammation in the brain, potentially benefiting people with conditions like MS that damage the nervous system.
Mitochondria are the cell compartments responsible for the production of energy in the body. Oxidative stress refers to cellular damage that occurs as a result of having high levels of oxidant molecules. -
Anavex - oversigt patenter.
Illustrerer hvor omfattende et arbejde der ligger i, at beskytte sig mod at andre løber med ens forskning.
Bemærk at 4-5 af patenterne ligger i sidste halvdel af 2019.
Efter eget udsagn er Anavex dækket godt ind på dette område nu, men de seneste patenter kunne måske tyde på, at der evt. kan har været huller i beskyttelsen og at Anavex derfor har holdt lidt lav profil med resultater og udviklingen af de forskellige forsøg. - bare en formodning.
Det virker også positivt, at man bruger så meget energi på at beskytte 2-73 - man må da have en relativ stor tiltro til, at skidtet virker.Neurodevelopmental disorder therapy
Patent number: 10507196
Abstract: This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
Type: Grant
Filed: January 24, 2017
Date of Patent: December 17, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventor: Christopher U. MisslingCRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
Publication number: 20190350892
Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
Type: Application
Filed: July 29, 2019
Publication date: November 21, 2019
Applicant: ANAVEX LIFE SCIENCES CORP.
Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter YorkA19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
Patent number: 10441563
Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.
Type: Grant
Filed: October 19, 2015
Date of Patent: October 15, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventors: Missling U. Christopher, Durrant CameronCrystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
Patent number: 10426754
Abstract: Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73. Method of treatment of Alzheimer's disease using pharmaceutical compositions comprising ANAVEX2-73 according to an intermittent dosage regimen.
Type: Grant
Filed: June 14, 2017
Date of Patent: October 1, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventor: Marco CecchiCrystal forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
Patent number: 10413519
Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3 -furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2 -diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
Type: Grant
Filed: July 19, 2016
Date of Patent: September 17, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter YorkAnalgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
Patent number: 10195192
Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof ("AV1066"), with reference to visceral and neuropathic pain.
Type: Grant
Filed: November 1, 2016
Date of Patent: February 5, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventor: Christopher U. MisslingANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
Patent number: 9750746
Abstract: This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.
Type: Grant
Filed: July 12, 2013
Date of Patent: September 5, 2017
Assignee: Anavex Life Sciences Corp.
Inventors: Alexandre Vamvakides, Tangui MauriceNEW SIGMA-RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR BIOCHEMICAL MECHANISMS WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION
Publication number: 20170129864
Abstract: The present invention involves new and original sigma receptors ligands: (Mono-or di-alkylaminoalkyl)-?-butyrolactones, their analogues aminotetrahydrofuranes, the (1-adamantyl) phenyl(s) alkylamines, the N,N Dialkyl ?-[(adamantyl-l)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or alkyl phenylamines, their enantiomers or diastereoisomers and their pharmaceutically acceptable salts, with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with anti-cancer, anti-metastatic, anti-(chronic) inflammatory, neuro-protective, anticonvulsive, antidepressive and nooanaleptic or sedative action.
Type: Application
Filed: February 26, 2013
Publication date: May 11, 2017
Applicant: Anavex Life Sciences Corp.
Inventor: Alexandre VamvakidesSigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity
Patent number: 9180106
Abstract: The present invention involves new and original sigma receptors ligands: (Mono- or dialkylaminoalkyl)-?-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl)benzene alkylamines, the N,N Dialkyl ?-[(adamantyl-1)benzyloxy-2]alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or -alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.
Type: Grant
Filed: March 12, 2014
Date of Patent: November 10, 2015
Assignee: Anavex Life Sciences Corp.
Inventor: Alexandre VamvakidesANAVEX2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITORS COMPOSITION AND METHOD FOR NEUROPROTECTION
Publication number: 20140296211
Abstract: This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.
Type: Application
Filed: July 12, 2013
Publication date: October 2, 2014
Applicant: ANAVEX LIFE SCIENCES CORP.
Inventors: Alexandre Vamvakides, Tangui MauriceSIGMA RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTI-CANCER ACTIVITY
Publication number: 20140228375
Abstract: The present invention involves new and original sigma receptors ligands: (Mono-or dialkylaminoalkyl)-?-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl ?-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.
Type: Application
Filed: March 12, 2014
Publication date: August 14, 2014
Applicant: Anavex Life Sciences Corp.
Inventor: Alexandre Vamvakides -
PTI - møde med UK myndigheder.
Grønt lys for fase 3 forsøg i UK.
The MHRA's scientific advice outlined a clear path forward toward the initiation and execution of the proposed two-pronged Phase 3 program,
-
Tasso, bare af almindelig interesse https://www.fiercebiotech.com/biotech/biogen-makes-another-alzheimer-s-bet-paying-pfizer-75m-for-early-phase-drug
-
Biogen har måske erkendt, at de må spille på andre heste også på Alzheimer området, hvis de ikke kan få presset FDA til at godkende fejlede aducanumab på bagrund af de meget tvivlsomme resultater.
Man forventede ellers et årlig salg på 12 milliarder $ ved en godkendelse af aducanumab.
Fortæller noget om, hvor stort potentialet er for den, der løser gåden helt eller bare delvis.Ser måske ud til, at den seneste medie omtale af Anavex i Forbes og MoneyShow top Picks for 2020 - og annoncering af patent m.m. begynder at give en vis effekt.
Volumen og kursen går da i den rigtig retning pt.
Profitable Advice from Investing and Trading Experts
Daily articles and videos featuring specific investment recommendations, stock picks and ETF recommendations for investors plus profitable trading strategies and trade ideas from top investing and trading experts.
Profitable Advice from Investing and Trading Experts (www.moneyshow.com)
-
Bedre link Anavex - Forbes/MoneyShow
7 Hot Drug Stocks To Buy In 2020
Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their favorite stocks for the coming year. Here are seven favorites from the pharmaceutical and biotechnology space.
Forbes (www.forbes.com)
-
Antyder du at BIIB har tilkøbt til eller frasolgt kandidater fra deres pipeline (se link). Sådan læste jeg din kommentar.
Jeg har ikke kunnet finde oplysninger, der bekræfter dette. Har du evt. et link?
-
Thorkild01 - link.
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind